Cobimetinib + Atezolizumab + Pembrolizumab
Phase 3Terminated 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced BRAFV600 Wild-type Melanoma
Conditions
Advanced BRAFV600 Wild-type Melanoma
Trial Timeline
Dec 11, 2017 → Feb 19, 2021
NCT ID
NCT03273153About Cobimetinib + Atezolizumab + Pembrolizumab
Cobimetinib + Atezolizumab + Pembrolizumab is a phase 3 stage product being developed by Roche for Advanced BRAFV600 Wild-type Melanoma. The current trial status is terminated. This product is registered under clinical trial identifier NCT03273153. Target conditions include Advanced BRAFV600 Wild-type Melanoma.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03273153 | Phase 3 | Terminated |
Competing Products
20 competing products in Advanced BRAFV600 Wild-type Melanoma